文献速递主动脉疾病

基于衰弱的风险评分预测择期胸主动脉瘤腔内修复术后并发症与死亡

A Frailty-Based Risk Score Predicts Morbidity and Mortality After Elective Endovascular Repair of Descending Thoracic Aortic Aneurysms.
PubMed 文献 · Ann Vasc Surg · 2019-11-06

本研究利用美国国家外科质量改进计划数据库2005-2016年择期胸主动脉瘤腔内修复(TEVAR)患者,开发并验证基于衰弱和手术复杂度的风险评分。结果显示功能依赖、肺部疾病、胸腹范围、髂动脉入路和Zone I/II锚定区是主要不良事件独立危险因素,评分可分层患者风险并预测术后死亡和主要并发症。

要点

  • 基于衰弱和手术复杂度的评分可预测TEVAR术后30天主要不良事件。
  • 功能依赖、肺部疾病、胸腹范围、髂动脉入路和Zone I/II锚定区是独立危险因素。
  • 低风险患者TEVAR安全,中风险需谨慎权衡,高风险可能不受益。

核心结论

  • 衰弱标记和手术复杂度可强烈预测择期TEVAR术后主要不良事件,有助于患者选择。

研究设计与样本

  • 回顾性队列研究,使用NSQIP数据库2005-2016年非急诊TEVAR患者,随机分为推导和验证样本,共纳入1784例。

主要发现

  • 推导队列14%发生主要不良事件(14%主要并发症,4%死亡)。
  • 独立危险因素包括功能依赖(OR 2.9,95%CI 1.6-5.4)、肺部疾病(OR 1.6,95%CI 1.1-2.4)、胸腹范围(OR 2.2,95%CI 1.4-3.4)、需髂动脉入路(OR 2.1,95%CI 1.1-3.8)和Zone I或II锚定区(OR 1.7,95%CI 1.1-2.5)。
  • 风险分层:低危(0分)、中危(1分)、高危(≥2分),死亡率分别为0%、4%、9%,主要并发症分别为7%、11%、23%。
  • 验证队列特征、风险分布和结局与推导队列相似,模型性能相近。

关键数值与推荐

  • 评分变量各赋1分:功能依赖、肺部疾病、胸腹范围、需髂动脉入路、Zone I或II锚定区。
  • 风险分层:0分为低危,1分为中危,≥2分为高危。

临床怎么用

  • 可用于择期TEVAR术前风险分层,辅助患者选择。
  • 低危患者可安全接受TEVAR,中危需充分讨论风险获益,高危可能不受益。

局限性

  • 需进一步研究明确衰弱与长期结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has expanded access to descending thoracic aortic aneurysm (DTAA) repair particularly for elderly and frail patients. This high-risk population has limited long-term overall survival, such that appropriate patient selection is required to optimize patient benefit and resource utilization. Our objective is to develop and validate a frailty-based, procedure-specific risk score for patients undergoing elective TEVAR for DTAA. METHODS: Patients undergoing nonemergent TEVAR for DTAA during 2005-2016 were identified in the National Surgical Quality Improvement Program database. Those with concurrent cardiac or open aortic surgery, abdominal visceral intervention, or Zone 0 deployment were excluded. Patients were randomly divided between derivation and validation samples. The primary outcome was 30-day major adverse events (MAE), including mortality and major systemic complications. Using the derivation cohort, variables associated with MAE were identified by univariable analyses. Those with P < 0.05 were included in multivariable logistic regression analysis. Independent procedure-specific and frailty-related risk factors for MAE were used to develop a pragmatic score to assess risk for TEVAR. RESULTS: Overall, 1,784 patients were included. 14% of the derivation patients had MAE (14% major complications, 4% mortality). Independent risk factors for MAE were primarily associated with markers of frailty and TEVAR extent and complexity and included functional dependence (OR 2.9, 95% CI 1.6-5.4), pulmonary disease (1.6, 1.1-2.4), thoracoabdominal extent (2.2 (1.4-3.4), need for iliac access (2.1, 1.1-3.8), and Zone I or II deployment (OR 1.7, 1.1-2.5). According to their respective beta coefficients, each variable was assigned a single point. Based on total points, patients were stratified as low- (0 points), intermediate- (1 point), or high-risk (≥2 points), with stepwise increases in mortality (0%, 4%, and 9%) and major complications (7%, 11%, and 23%) between strata. Validation patients had similar characteristics, risk strata distribution, and outcomes as the derivation patients, and the risk model had similar performance in both groups. CONCLUSIONS: Markers of frailty and procedure complexity strongly predict MAE after TEVAR for DTAA and can improve patient selection by enabling patient and procedure-specific risk stratification. While TEVAR is safe in low-risk patients, intermediate-risk patients warrant careful discussion of the risks and benefits of aortic intervention; under certain circumstances, high-risk patients may not benefit. Further study is required to define the association between frailty and long-term outcomes.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Harris DG, Olson SL, Panthofer AM, et al. A Frailty-Based Risk Score Predicts Morbidity and Mortality After Elective Endovascular Repair of Descending Thoracic Aortic Aneurysms. Ann Vasc Surg. 2019. PMID: 31705983. doi:10.1016/j.avsg.2019.10.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。